

4<sup>th</sup> November 2022

BSE LIMITED Phiroze Jeejeebhoy Towers Dalal Street, Mumbai – 400001  <b>Scrip Code: BSE – AJANTPHARM 532331</b>	National Stock Exchange of India, Exchange Plaza, 5 <sup>th</sup> Floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051  <b>Scrip Code: NSE AJANTPHARM EQ</b>
--	--

**Sub.: Compliance Under Regulation 47 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 ('Listing Regulations')**

Dear Sir/Madam,

Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the second quarter and half year ended 30<sup>th</sup> September 2022 published in following newspapers on 4<sup>th</sup> November 2022:

1. Mumbai edition of Economic Times and
2. Mumbai edition of Maharashtra Times;

This is for your information and record.

Yours faithfully,

**GAURANG SHAH**

*VP - Legal & Company Secretary*

*Encl.: a/a*

**TAMING FOOD INFLATION GETS TOUGHER**

# Prices of Kitchen Staples Shoot Up Post Festive Season

Sutanuka Ghosal & Jayashree Bhosale

**Kolkata | Pune:** Prices of kitchen essentials like wheat, rice and cooking oils have gone up after Diwali. Even milk prices are expected to remain firm in the second half of FY22. This will be added worries for the government trying to put a lid on food inflation.



While wheat prices have gone up by up to 7% as the speculators are at play, rice prices have gone up by up to 7% after government allowed export of 6 lakh tonnes of paddy to Nepal. Also, there is a shortage in supply of 1121 variety of basmati rice, which is used in biryani, in the market pushing up prices of all types of basmati.

Prices of edible oils, which is the main medium of cooking in Indian households, too have gone up by up to 8% after Diwali as international prices have started moving northwards.

A price surge in wheat has made eating roti, paratha, puri, upma, bread, pizza or noodles even more expensive in the past month as prices of atta and other wheat products have sharply moved up.

"Wheat prices in Delhi have moved up by 8% in October, while the increase in consumer end prices is even higher. Every year during winter season, demand for atta goes up as people eat more due to good appetite and the marriage season," said Navneet Chitlangia, wheat processor from Rajasthan. In the past three weeks prices have increased 4-8% in different states.

Non-basmati rice, which is main staple in most Indian households across the country, saw price increase of 3%-4% in last two days after government allowed exports of 6 lakh metric tonnes of paddy to Nepal, said Suraj Agarwal, CEO of Rice Villa. He added that basmati rice prices too have shot up after Diwali as the supply of 1121 variety of basmati rice is lower.

"This has pushed up prices of all kinds of basmati rice," Agarwal added. The availability of rice this year will be less as kharif rice production is estimated to be at 104.99 million tonnes during the current season in wake of uneven monsoon, which is 6% lower than the production of 111.76 million tonnes in the last season.

Cooking oil prices, which had bottomed out in September, giving some relief to the consumer, is again moving upwards.

## Scant Funds for Poor Developing Nations' Climate Change Efforts: UN

Urmi Goswami  
@timesgroup.com

**New Delhi:** The impact of climate change—heatwaves, floods, droughts—is becoming more frequent and intense, yet poor developing countries on the frontlines with the least capacity to adapt receive the least amount of support, the United Nations has said.

By 2030, developing countries will need anywhere between \$160 billion and \$340 billion a year to adapt to the impacts of a warming planet but financial flows to support adaptation efforts of these countries are nowhere near what is required, the 2022 edition of the UN Environment Programme Adaptation Gap Report has said.

In 2020, rich countries provided only \$29 billion as adaptation finance to poor developing countries, it said.

Even when developing countries have drawn up clear plans for adapting to the impacts of climate change, the funding required to act on these plans is not available, the report said.

Rwanda, for example, developed its Strategic Plan for Climate Resilience in 2017. The plan identified four programmes requiring a total investment of \$534 million. Yet, till date, little of the required funding has materialised.

Adaptation remains underfunded even though it remains the overriding need of many developed countries. Nearly 84% of 197 countries that are signatories to the UN Framework Convention on Climate Change have adaptation plans, strategies, laws and policies in place. A third of these countries have set quantified and time-bound targets.

With COP27 in Egypt just days away, UN secretary general Antonio Guterres has called on countries to turn the tide.

"Adaptation must be treated with a seriousness that reflects the equal worth of all members of the human family," he said. "It's time for a global climate adaptation overhaul that puts aside excuses and picks up the toolbox to fix the problems."

The gap report demonstrates global efforts in adaptation planning, financing and implementation are not keeping pace with the growing risks.

Annual adaptation needs, according to the 2022 report, are expected to increase to between \$315 billion and \$565 billion by 2050.

At Glasgow, rich industrialised countries had committed to double financial flows for adaptation.

## 'Govt Mapping Laboratories to Plug Critical Gaps'

Press Trust of India

**New Delhi:** The government is mapping all laboratories in the country in a bid to plug the critical gaps and modernise them to make India a quality-conscious country. Food and Consumer Affairs Minister Piyush Goyal said on Thursday. State-run Bureau of Indian Standards (BIS) has already mapped 3,000-odd NABL-accredited non-diagnostic laboratories in the country. It is mulling how to map the non-accredited non-diagnostic labs set up by PSUs, industries and education institutes like IITs.

Addressing a day-long seminar on 'Emerging global trends in laboratories for self-reliant India', Goyal said: "Unless we are leaders in quality, we will not be able to become a developed nation and leverage the fruits of international engagement that we are trying to expand." The time is right to engage with the private sector, he said.

## SC Status Quo on Move to Allow GM Mustard Sowing

Our Bureau

**New Delhi:** The Supreme Court on Thursday ordered status quo on the government move to allow cultivation of genetically modified (GM) mustard in the country, barring its planting until the top court completes hearing a plea opposing the decision.

This comes days after the country's regulator of genetically modified plants and food products approved 'environmental release' of Dhara Mustard Hybrid-II (DMH-II), a genetically-engineered variant of mustard developed by Centre for Genetic Manipulation of Crop Plants at Delhi University.

A bench of the Supreme Court has scheduled the next hearing in the matter for November 10.

Aruna Rodrigues, lead petitioner for the case, argued that GM mustard is an herbicide tolerant crop that can cause serious effects on human health and will also contaminate normal mustard.

# Mahindra LIFESPACES

## Mahindra Lifespace Developers Limited (Consolidated)

CIN - L45200MH1999PLC118949 Tel.: 022-67478600

Website: www.mahindralifespaces.com

Registered Office :- Mahindra Towers, 5th Floor, Worli, Mumbai - 400018

Extract of Consolidated Unaudited Financial Results For The Quarter and Half year ended 30th September, 2022

(Rs. In Lakhs)

Sr. No.	Particulars	Quarter Ended 30.09.2022 Unaudited	Half Year Ended 30.09.2022 Unaudited	Quarter Ended 30.09.2021 Unaudited
1	Total Income (Including Other Income)	7,382	19,116	6,570
2	(Loss) / Profit For The Period (Before Tax and Exceptional Items)	(4,105)	(5,443)	1,219
3	(Loss) / Profit For The Period Before Tax (After Exceptional Items)	(4,105)	(2,061)	1,219
4	Share in Profit of Joint Venture and Associates	2,680	8,962	1,174
5	(Loss) / Profit For The Period Before Tax (After Exceptional Items and after Profit of Joint Venture and Associates)	(1,425)	6,901	2,393
6	(Loss) / Profit For The Period After Tax (After Exceptional Items and after Profit of Joint Venture and Associates)	(751)	6,819	1,323
7	Total Comprehensive (Loss) / Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(751)	6,819	1,323
8	Paid-up Equity Share Capital (Face Value of Rs.10/- each)	15,458	15,458	15,418
9	Earning Per Share (Face value of Rs. 10/- each) *			
	1. Basic Earnings per Share (Rs.)	(0.50)	4.38	0.86
	2. Diluted Earnings per Share (Rs.)	(0.50)	4.35	0.85

\* Basic and Diluted EPS for all periods, are not annualised.

**Notes:**

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors of the Parent Company at their meeting held on 03rd November, 2022. The unaudited consolidated financial results for the quarter and half year ended 30th September 2022 have been subjected to limited review by the statutory auditors, Deloitte Haskins & Sells LLP, who have expressed an unmodified opinion.

2. Key Numbers of Standalone Financials Results:-

(Rs. In Lakhs)

Particulars	Quarter Ended 30.09.2022 Unaudited	Half Year Ended 30.09.2022 Unaudited	Quarter Ended 30.09.2021 Unaudited
Total Income (Including Other Income)	5,172	12,389	3,293
(Loss) / Profit Before Tax after Exceptional Items	(2,723)	5,627	(520)
(Loss) / Profit after Tax	(1,999)	5,664	(430)

3. The above is an extract of the detailed format of financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulation, 2015. The full format of financial results are available on the Stock Exchange website, www.nseindia.com and www.bseindia.com and on the Company's website www.mahindralifespaces.com.

For and on Behalf of the Board

**Arvind Subramanian**

Managing Director

DIN: 02551935

Place: Mumbai

Dated : 03rd November, 2022

# ajanta pharma limited

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,

Phone - +91-22-66061000, Fax - +91-22-66061200

CIN - L24230MH1979PLC022059

Email - info@ajantapharma.com, Website - www.ajantapharma.com

## Extract of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2022

₹ in Crore

Particulars	Quarter ended 30-Sep-22	Half year ended 30-Sep-22	Quarter ended 30-Sep-21	Year ended 31-Mar-22
1 Total Income from Operations	938.10	1,889.03	884.80	3,340.99
2 Net Profit for the period before tax (before exceptional and/or extraordinary items)	203.00	424.86	260.42	909.48
3 Net Profit for the period before tax (after exceptional and/or extraordinary items)	203.00	424.86	260.42	909.48
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	156.60	331.22	195.94	712.68
5 Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	158.57	338.49	191.69	704.71
6 Equity Share Capital	25.71	25.71	17.39	17.17
7 Reserve (excluding Revaluation Reserve) as shown in audited balance sheet				3,247.17
8 Earnings Per Share (FV of ₹ 2/- each)				
(a) Basic - in ₹	12.22	25.85	15.10	54.97
(b) Diluted - in ₹	12.22	25.85	15.10	54.96

### Key information on Standalone Financial Results :

Particulars	Quarter ended 30-Sep-22	Half year ended 30-Sep-22	Quarter ended 30-Sep-21	Year ended 31-Mar-22
Total Income from Operations	837.23	1,687.52	823.71	3,140.64
Profit Before Tax	206.59	396.94	254.79	900.54
Profit After Tax	167.18	317.55	196.85	719.86
Total Comprehensive Income	166.49	316.96	196.54	720.22

**Notes:**

- The above unaudited financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 3 November 2022.
- Board of Directors have approved payment of interim dividend on 3 November 2022 of ₹ 7 per equity share of face value of ₹ 2 each.
- The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and half year ended 30 September 2022 are available on stock exchange websites www.nseindia.com and www.bseindia.com and on Company's website www.ajantapharma.com.

By order of the Board  
For Ajanta Pharma Ltd.


Sd/-  
**Yogesh M. Agrawal**  
Managing Director

Mumbai, 3 November 2022



## PDS Limited

(erstwhile PDS Multinational Fashions Limited)



Note: ROCE based on Net Capital Employed, EBIT includes other income emanating from capital employed | Normalized PBT is adjusted for gain from sale of real estate, ESOP cost, new business | EPS mentioned is Basic EPS

### Extract of Consolidated Financial Results for the quarter and half year ended September 30, 2022

(All amounts in ₹ lakhs, unless otherwise stated)

Sr. No.	Particulars	Quarter ended		Half year ended		Year ended	
		30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)		30.09.2021 (Unaudited)
1	Revenue from operations	292,122.22	234,037.49	219,488.85	526,159.71	382,110.09	882,821.38
2	Other income	3,941.95	268.22	1,093.49	4,210.17	5,957.72	8,602.74
3	Total income	296,064.17	234,305.71	220,582.34	530,369.88	388,067.81	891,424.12
4	Total operating expense	283,646.39	229,527.87	213,460.31	513,174.26	374,849.00	860,358.46
5	Earnings before interest and tax	13,839.43	5,704.33	7,849.49	19,543.76	14,420.84	33,867.49
6	Net profit for the period/year (before tax and exceptional items)	12,417.78	4,777.84	7,122.03	17,195.62	13,218.81	31,065.66
7	Net profit for the period/year before tax (after exceptional items and share of loss from associates and joint ventures)	12,425.83	4,729.65	7,090.00	17,155.48	13,268.53	31,007.80
8	Net profit for the period/year after tax (after exceptional items and share of loss from associates and joint ventures)	11,328.73	4,417.89	6,682.86	15,746.62	12,592.97	29,282.09
9	Total comprehensive income for the period/year (comprising profit/(loss) for the period (after tax) and other comprehensive income (after tax))	10,427.42	5,985.57	6,095.49	16,412.99	13,548.46	32,639.71
10	Paid up equity share capital (face value of ₹2 each)	2607.95*	2609.25*	2604.45*	2607.95*	2604.45*	2,604.25
11	Other Equity						84,635.94
12	Earnings(loss) per share (in ₹) (face value of ₹ 2 each) - (not annualised)						
	Basic	7.19	2.84	3.97	10.03	8.10	19.08
	Diluted	7.05	2.78	3.93	9.84	8.04	18.86

\* Net of issue of fresh capital & Treasury shares 86,225 (as at 30 September 2021 - 11,225)

**Note:**

- The Financial Results of the Company/Group for the quarter and half year ended 30 September 2022, have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 02 November 2022 and have been reviewed by the Statutory Auditors.
- The financial performance of the company on standalone basis for the quarter and half year ended 30 September 2022 are (₹ in lakhs):

Particulars	Quarter ended		Half year ended		Year ended	
	30.09.2022 (Unaudited)	30.06.2022 (Unaudited)	30.09.2021 (Unaudited)	30.09.2022 (Unaudited)		30.09.2021 (Unaudited)
Turnover	9,748.25	4,049.59	3,436.81	13,797.84	4,795.78	11,582.72
Profit before tax	531.01	551.25	545.45	1,082.26	697.20	7,016.28
Profit After tax	400.26	416.16	416.82	816.42	530.61	6,678.86
Total comprehensive income	394.74	413.97	540.60	808.71	654.39	6,695.43

c) The above is an extract of detailed format of financial results filed with the stock exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosures requirements) Regulation 2015. The full format of the Unaudited financial results of the Group and the Company for the quarter and half year ended 30 September 2022 are available on the Company's website (www.pdsinternational.com) and on the website of BSE (www.bseindia.com) and NSE (www.nseindia.com).

For and on behalf of the Board of Directors  
PDS Limited  
(erstwhile PDS Multinational Fashions Limited)

(Deepak Seth)  
Chairman  
DIN: 00003021

Place : Mumbai  
Date : 2-Nov-2022

CIN: L18101MH2011PLC388088

Registered Office: Unit No. 971, Solitaire Corporate Park, Andheri Ghatkopar Link Road, Andheri East, Mumbai-400093, Maharashtra, India | Tel: +91 80 67653000; +91 22 41441100;

Email: investors@pdsind.com; Website: www.pdsinternational.com

# 'वैद्यकीय'चे पुनश्च हरिओम

युकेनहून परतलेल्या विद्यार्थ्यांना प्रथम वर्षालाच प्रवेश

म. टा. प्रतिनिधी, नाशिक

रशिया-युकेन युद्धामुळे युकेनमधून परतलेल्या वैद्यकीय अभ्यासक्रमांच्या विद्यार्थ्यांचे शिक्षणाचे पहिले वर्ष वाया गेले असून, या विद्यार्थ्यांना पुन्हा पहिल्या वर्षाला प्रवेश घ्यावा लागला आहे. या नवीन प्रवेशापोटी पालकांना ८ ते १० लाख रुपये खर्च करावे लागले असून, गेल्या वर्षीचा संपूर्ण खर्च वाया गेल्याची खंत पालकांमधून व्यक्त होत आहे.

फेब्रुवारी-मार्चदरम्यान झालेल्या रशिया-युकेन युद्धामध्ये भारतातून युकेनमध्ये वैद्यकीय शिक्षणासाठी गेलेले जवळपास १६ हजार विद्यार्थी भारतात परतले होते. त्यापैकी जवळपास ५ हजार विद्यार्थी पहिल्या वर्षाचे होते. युद्धामुळे अभ्यासक्रम सुरू होताच भारतात परतल्या लागलेल्या या विद्यार्थ्यांचे पहिले संपूर्ण शैक्षणिक वर्ष वाया गेले असून, त्यांना शैक्षणिक वर्ष २०२२-२३ मध्ये पुन्हा नव्याने पहिल्या वर्षाला प्रवेश घ्यावा लागला आहे. या विद्यार्थ्यांनी प्रवेशासाठी रशियाला सर्वाधिक पसंती दिली असून, काही विद्यार्थ्यांनी जॉर्जिया, उझबेकिस्तान, कझाकस्तान, पोलंड, हंगेरी या देशांमध्ये प्रवेश घेतला आहे. या देशांमध्ये प्रवेशाचा खर्च जवळपास ८ ते १२ लाखांदरम्यान आल्याची माहिती



■ युद्ध परिस्थितीमुळे युकेनमधील विद्यापीठांमार्फत ट्रान्सक्रिप्ट न मिळाल्यामुळे अन्य देशांमधील विद्यापीठात दुसऱ्या वर्षाला प्रवेश मिळवण्यामध्ये या विद्यार्थ्यांना अडचणी येत होत्या.

■ केवळ तीन ते चार महिने युकेनमध्ये राहून युद्धामुळे या विद्यार्थ्यांना परत यावे लागले होते.

■ काही काळ ऑनलाइन शिक्षण मिळालेले असले, तरी या विद्यार्थ्यांना योग्य पद्धतीने प्रथम वर्षाचे वैद्यकीय शिक्षण मिळालेले नव्हते.

■ हे शैक्षणिक नुकसान भरून काढण्यासाठी पुन्हा पहिल्या वर्षाला प्रवेश घेणे उपयुक्त ठरणार असल्याचे या क्षेत्रातील तज्ज्ञांनी सांगितले.

“मी युकेनमधील इंप्रोव्हिया विद्यापीठात गेल्या वर्षी वैद्यकीय शिक्षणाला प्रवेश घेतला होतो. आता रशियामधील विद्यापीठात प्रवेश घेतला आहे. युकेनमध्ये पहिल्या वर्षाचे वैद्यकीय शिक्षण घेणारे महाराष्ट्रातील जवळपास ७०० ते ८०० विद्यार्थी होते. या सर्वांना पहिल्या वर्षाला पुन्हा प्रवेश घ्यावा लागला आहे.

— किरण गोरे, विद्यार्थी

विद्यार्थ्यांनी दिली. गेल्यावर्षी जवळपास ८ ते १० लाख रुपये खर्च करून युकेनच्या विविध विद्यापीठांमध्ये प्रवेश घेतला होता. आता पुन्हा तितकाच खर्च प्रवेशासाठी करावा लागला आहे.

## पत्नीला गाडी शिकवताना अपघात

म. टा. वृत्तसेवा, बुलढाणा

पत्नीला कार चालवणे शिकवताना कारवरील नियंत्रण सुटल्याने कार रस्त्याच्या बाजूला असलेल्या विहिरीत कोसळली. या भीषण अपघातात पत्नीसह मागे बसलेल्या मुलीचा मृत्यू झाला. पती गंभीर जखमी आहे. या कुटुंबाच्या मदतीसाठी विहिरीत उडी घेतलेल्या एका युवकाचाही बचावकार्यादरम्यान मृत्यू झाला.

**मोटर विहिरीत पडली; मायलेकीसह आणखी एक ठार**

जिल्ह्यातील देऊळगाव राजा-चिखली मार्गावर गुरुवारी दुपारी २ वाजताच्या सुमारास ही घटना घडली. स्वाती अमोल मुरकुटे (वय ३५), सिद्धी अमोल मुरकुटे (वय ११) व पवन पिंपळे (वय २५)

अशी मृतकांची नावे आहेत. अमोल मुरकुटे (वय ३९) जखमी असून त्यांच्यावर उपचार सुरू आहेत. देऊळगाव राजा शहरातील रामनगर भागात राहणारे शिक्षक अमोल मुरकुटे हे दिवाळीच्या सुट्ट्या असल्याने त्यांची पत्नी स्वातीला कार चालवणे शिकवत होते. त्यांच्यासोबत त्यांची पाचव्या वर्गात शिकणारी मुलगी सिद्धी गाडीत मागे बसली होती. दरम्यान, चिखली मार्गावरील हॉटेल विजयजवळ कारवरील

नियंत्रण सुटले. वेगात निघाली. थेट रस्त्याच्या कडेला असलेल्या ७० फूट खोल विहिरीत कोसळली. यावेळी अमोल हे कसेबसे खिडकीतून बाहेर आले. मात्र पत्नी आणि मुलीला वाचविण्याचा प्रयत्न करू लागले. मात्र त्यांना यात यश आले नाही. यावेळी नागरिकही मदतीसाठी धावले. गर्दी झाली. बचाव पथकाची प्रतीक्षा सुरू असताना देऊळगाव राजा येथील पवन पिंपळे या युवकाने मदतीसाठी विहिरीत उडी मारली. मात्र



बराच वेळ झाला तरी तो बाहेर आला नाही. त्याचा मृत्यू झाला. अग्निशमन दल आणि पोलिसांनी तिघांचेही मृतदेह विहिरीतून बाहेर काढले. या दाम्पत्याला एक मुलगा आहे. तो ट्युशनला गेला असल्यामुळे कारमध्ये नव्हता.

**Siyaram's**

PREMIUM SUITINGS & SHIRTINGS

**SIYARAM SILK MILLS LTD.**

CIN : L17116MH1978PLC020451

Regd. Office: H-3/2, MIDC, 'A' Road, Tarapur, Boisar, Dist. Palghar, PIN 401 506 (M.S.),  
Phone - 7506794051; Email - sharedept@siyaram.com; Website - www.siyaram.com

**EXTRACT OF STANDALONE AND CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30<sup>TH</sup> SEPTEMBER, 2022.** (₹ In Lakhs)

PARTICULARS	Standalone				Consolidated			
	Quarter Ended 30.09.2022 (Unaudited)	Half Year Ended 30.09.2022 (Unaudited)	Quarter Ended 30.09.2021 (Unaudited)	Year Ended 31.03.2022 (Audited)	Quarter Ended 30.09.2022 (Unaudited)	Half Year Ended 30.09.2022 (Unaudited)	Quarter Ended 30.09.2021 (Unaudited)	Year Ended 31.03.2022 (Audited)
Revenue from Operations	63,547	1,03,343	47,991	1,90,307	63,576	1,03,490	48,037	1,90,496
Other Income	928	1,670	650	3,445	932	1,676	650	3,445
Total Income	64,475	1,05,013	48,641	1,93,752	64,508	1,05,166	48,687	1,93,941
Net Profit for the period Before Tax	10,874	15,009	7,167	28,682	10,835	14,957	7,130	29,054
Net Profit for the period After Tax	8,052	11,150	5,326	21,251	8,013	11,098	5,289	21,623
Total Comprehensive Income	8,060	11,169	5,306	21,306	8,012	11,103	5,263	21,670
Paid up Equity Share Capital (Face value of ₹ 2/- per share)	937	937	937	937	937	937	937	937
Earnings Per Share (of ₹ 2/- each)								
Basic and Diluted (₹) (not annualised)	17.18	23.79	11.37	45.34	17.10	23.68	11.29	46.14

**Notes:**

- The above unaudited Standalone and Consolidated financial result of the Company for the quarter and half year ended September 30, 2022 have been reviewed by the Audit Committee and thereafter approved by the Board of Directors at their meeting held on November 3, 2022. The Statutory Auditors have carried out a limited review of these results.
- The Board has declared an Interim Dividend of ₹ 4/- (200%) per equity share of ₹ 2/- each. The cash outgo on account of Interim Dividend will be ₹ 1,874.80 Lakhs.
- The above is an extract of the detailed format of Standalone and Consolidated Unaudited Financial Results for the quarter and half year ended 30<sup>th</sup> September 2022 filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of financial results are available on the Stock Exchange websites, [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on the Company's website [www.siyaram.com](http://www.siyaram.com).

For SIYARAM SILK MILLS LTD.  
Sd/-

(Ramesh Poddar)  
Chairman & Managing Director  
DIN : 00090104

Place : Mumbai  
Date : 03/11/2022

**J. HAMPSTEAD**  
WORLD'S FINEST FABRIC & APPAREL

**MiSTAIR**  
IMPACT DRESSING  
A quality product from **Siyaram's**

**Siyaram's**  
ROYAL LÉ LINEN  
premium linen fabric

**OXEMBERG**

**Siyaram's**  
MOZZO

**Siyaram's**  
INSPIRO

**GOVERNMENT OF INDIA**  
**MINISTRY OF HEALTH & FAMILY WELFARE**  
**OFFICE OF THE ADDITIONAL DIRECTOR**  
**CENTRAL GOVERNMENT HEALTH SCHEME, MUMBAI**  
Old CGO Building (Pratishtha Bhavan), Ground Floor, South Wing, 101, M.K. Road, New Marine Lines, Mumbai 400020, Tel. No. 22018600/22018648 Fax. 22018612  
Website : cghsmumbai.gov.in, E-mail: ad.mum@cgshs.nic.in

**PRESS NOTE**

CGHS Mumbai, Ministry of Health and Family Welfare invites applications from the retired Government Staff for the following posts on contractual basis.

Name of CGHS City	Post	Number of Post	
		Mumbai	Goa
MUMBAI	Pharmacist (Allopathic)	21	----
	Lower Division Clerk	21	01
	MA/MTS	23	----
	LMA/MTS	12	----
	Nursing Officer	06	----

Candidates are requested to visit [cghs.gov.in](http://cghs.gov.in) for complete details and corrigendum if any issued from time to time in section Advertisement and Tender under the heading of Circulars. Last date of application 19/11/2022.

Dr Nirmal Mandal  
Additional Director  
CGHS Mumbai

**ajanta pharma limited**

Regd. Office: 'Ajanta House', Charkop, Kandivli (W), Mumbai-67,  
Phone - +91-22-66061000, Fax - +91-22-66061200  
CIN - L24230MH1979PLC022059  
Email - [info@ajantapharma.com](mailto:info@ajantapharma.com), Website - [www.ajantapharma.com](http://www.ajantapharma.com)

**Extract of Unaudited Consolidated Financial Results for the quarter and six months ended 30 September 2022**

₹ in Crore

Particulars	Quarter ended 30-Sep-22	Half year ended 30-Sep-22	Quarter ended 30-Sep-21	Year ended 31-Mar-22
1 Total Income from Operations	938.10	1,889.03	884.80	3,340.99
2 Net Profit for the period before tax (before exceptional and/or extraordinary items)	203.00	424.86	260.42	909.48
3 Net Profit for the period before tax (after exceptional and/or extraordinary items)	203.00	424.86	260.42	909.48
4 Net Profit for the period after tax (after exceptional and/or extraordinary items)	156.60	331.22	195.94	712.68
5 Total Comprehensive Income for the period (comprising profit for the period after tax and other comprehensive income after tax)	158.57	338.49	191.69	704.71
6 Equity Share Capital	25.71	25.71	17.39	17.17
7 Reserve (excluding Revaluation Reserve) as shown in audited balance sheet				3,247.17
8 Earnings Per Share (FV of ₹ 2/- each)				
(a) Basic - in ₹	12.22	25.85	15.10	54.97
(b) Diluted - in ₹	12.22	25.85	15.10	54.96

**Key information on Standalone Financial Results :**

Particulars	Quarter ended 30-Sep-22	Half year ended 30-Sep-22	Quarter ended 30-Sep-21	Year ended 31-Mar-22
Total Income from Operations	837.23	1,687.52	823.71	3,140.64
Profit Before Tax	206.59	396.94	254.79	900.54
Profit After Tax	167.18	317.55	196.85	719.86
Total Comprehensive Income	166.49	316.96	196.54	720.22

**Notes:**

- The above unaudited financial results have been reviewed by Audit Committee and thereafter approved by the Board of Directors at their meeting held on 3 November 2022.
- Board of Directors have approved payment of interim dividend on 3 November 2022 of ₹ 7 per equity share of face value of ₹ 2 each.
- The above is an extract of the detailed format of Quarterly Financial Results filed with Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the standalone and consolidated financial results for the quarter and half year ended 30 September 2022 are available on stock exchange websites [www.nseindia.com](http://www.nseindia.com) and [www.bseindia.com](http://www.bseindia.com) and on Company's website [www.ajantapharma.com](http://www.ajantapharma.com).

By order of the Board  
For Ajanta Pharma Ltd.

Sd/-  
Yogesh M. Agrawal  
Managing Director

Mumbai, 3 November 2022



**हॉकिन्स कुकर्स लिमिटेड**

नोंदणीकृत कार्यालय: मेकर टॉवर एफ 101, कफ परेड, मुंबई 400005.  
कॉर्पोरेट आयडेंटिटी नंबर: L28997MH1959PLC011304  
फोन: 022-22186607, फॅक्स: 022-22181190  
[ho@hawkinscookers.com](mailto:ho@hawkinscookers.com) □ [www.hawkinscookers.com](http://www.hawkinscookers.com)

**वित्तीय परिणामांचा गोषवाऱा (₹. कोटी)**

	संपलेली तिमाही		संपलेली सहामाही
	सप्टें. 2022	सप्टें. 2021	
1) प्रचलनाद्वारे एकूण उत्पन्न/महसूल (सूट वजा जाता)	297.33	266.19	495.07
2) कालावधीसाठी करपूर्व निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण मुद्दे पूर्व)	41.32	35.23	72.24
3) कालावधीसाठी करपूर्व निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण मुद्दे पश्चात)	41.32	35.23	72.24
4) कालावधीसाठी करपश्चात निव्वळ नफा (अपवादात्मक आणि/किंवा असाधारण मुद्दे पश्चात)	30.82	26.24	53.88
5) कालावधीसाठी एकूण सर्वसमावेशक मिळकत (कालावधीचा करपश्चात नफा आणि इतर सर्वसमावेशक करपश्चात मिळकत सह)	30.99	26.02	54.23
6) भ्रणा केलेले इक्विटी समभाग भांडवल	5.29	5.29	5.29
7) राखीव निधी, पुनर्मुल्यांकित राखीव निधी वगळता (मागील/पूर्ण झालेल्या वर्षाच्या अखेरीसच्या ताळेबंदात दाखविल्याप्रमाणे)	207.89	172.34	207.89
8) प्रतिसमभाग मिळकत रूपात (प्रत्येकी ₹.10च्या समभागावर, बेसिक व डायल्युटेड)	58.28	49.62	101.90

**टीपा:** सेबी (लिस्टिंग ऑव्लिगेशन्स व प्रगटिकरणाच्या आवश्यकता) अधिनियम, 2015 मधील नियम 33 अन्वये वीएसई लिमिटेड यांच्याकडे सादर करण्यात आलेल्या दिनांक 30 सप्टेंबर 2022 रोजी संपलेल्या तिमाही/सहामाहीच्या तपशिलवार वित्तीय परिणामांचा गोषवाऱा वर देण्यात आला आहे. सादर तपशिलवार स्वरूपातील तिमाही/सहामाहीचे वित्तीय परिणाम वीएसई लिमिटेड यांच्या वेबसाईटवर [www.bseindia.com](http://www.bseindia.com) आणि कंपनीच्या वेबसाईटवर [www.hawkinscookers.com](http://www.hawkinscookers.com) उपलब्ध आहेत.

मुंबई  
3 नोव्हेंबर 2022

करिता हॉकिन्स कुकर्स लिमिटेड  
सुदीप यादव, व्हाईस चेअरमन आणि चीफ फायनान्शियल ऑफिसर

**mini**  
CASSEROLE  
मिनी कॅसरोल



कुक. सर्व. स्टोअर. रिहिट. इट.

अधिक माहितीसाठी

